Treatment and Prevention of Oral Thrush in High-Risk Populations

Special Considerations for High-Risk Neonates

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommends against the use of miconazole oral gel in infants due to the risk of airway obstruction and potential for triazole resistance 1
In nurseries with invasive candidiasis rates >10%, prophylactic fluconazole 3-6 mg/kg twice weekly for 6 weeks is recommended to prevent progression to invasive candidiasis in extremely low birth weight infants 2
Prophylaxis with fluconazole should be considered on an individual basis in units with lower incidence of invasive candidiasis, as it can prevent progression to invasive disease in high-risk neonates 1

Systemically absorbed antifungals, such as fluconazole, should be used in immunocompromised children when there is a risk of dissemination, as non-absorbed agents like nystatin are insufficient in these cases 1

The American Academy of Pediatrics recommends fluconazole (3-6 mg/kg daily) as an effective alternative to nystatin when it fails or cannot be used 3
Fluconazole has a half-life of 55-90 hours in neonates, allowing for once-daily dosing 4

In nurseries with high rates of invasive candidiasis, the Centers for Disease Control and Prevention recommends prophylactic fluconazole (3-6 mg/kg twice weekly for 6 weeks) for neonates with birth weights <1000g 5, 6
For candidemia without obvious metastatic complications, treatment is recommended for 2 weeks after documented clearance of Candida species and resolution of attributable signs 3